Radiation Oncology Journal

  • 제31권1호
  • /
  • Pages.25-33
  • /
  • 2013
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience

  • Kim, Kyung Hwan (Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei University Health System) ;
  • Chang, Jee Suk (Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei University Health System) ;
  • Keum, Ki Chang (Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei University Health System) ;
  • Ahn, Joong Bae (Department of Internal Medicine, Yonsei University College of Medicine, Yonsei University Health System) ;
  • Lee, Chang Geol (Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei University Health System) ;
  • Koom, Woong Sub (Department of Radiation Oncology, Yonsei University College of Medicine, Yonsei University Health System)
  • 투고 : 2012.12.23
  • 심사 : 2013.02.18
  • 발행 : 2013.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: We reviewed the treatment outcomes and prognostic factors for patients with anal canal carcinoma who were treated with curative intent chemoradiotherapy (CRT) at Severance Hospital from 2005 to 2011. Materials and Methods: Data for 38 eligible patients treated during this period were reviewed. All patients were treated with curative intent using radiotherapy (RT) with (n = 35) or without concomitant chemotherapy (n = 3). Among 35 patients who received CRT, most of the chemotherapeutic regimens were either 5-fluorouracil (5-FU) plus mitomycin C (23 patients) or 5-FU plus cisplatin (10 patients). Recurrence-free survival (RFS), colostomy-free survival (CFS), overall survival (OS), and locoregional control (LRC) rates were calculated using the Kaplan-Meier method and survival between subgroups were compared using the log-rank test. Cox's proportional hazard model was used for multivariate analysis. Results: Over a median follow-up period of 44 months (range, 11 to 96 months), 3-year RFS, CFS, OS, and LRC were 80%, 79%, 85%, and 92%, respectively. In multivariate analysis, tumor size >4 cm was an independent predicting factor for poorer RFS (hazard ratio [HR], 6.35; 95% confidence interval [CI], 1.42 to 28.5; p = 0.006) and CFS (HR, 6.25; 95% CI, 1.39-28.0; p = 0.017), while the presence of external iliac lymph node metastasis was an independent prognosticator for poorer OS (HR, 9.32; 95% CI, 1.24 to 70.3; p = 0.030). No treatment-related colostomies or deaths occurred during or after treatment. Conclusion: Curative intent CRT resulted in excellent outcomes that were comparable to outcomes in previous randomized trials. No severe treatment-related toxicities were observed.

키워드

참고문헌

  1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36. https://doi.org/10.3322/canjclin.51.1.15
  2. The Korea Central Cancer Registry, National Cancer Center, Ministry of Health and Welfare. Annual report of cancer statistics in Korea in 2008 [Internet]. Goyang: National Cancer Center; c2010 [cited 2010 Dec]. Available from: http://ncc.re.kr/manage/manage03_033_view.jsp?bbsnum=189&hSelSearch=&hTxtKeyword=¤t_page=1&cd=null.
  3. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996;348:1049-54. https://doi.org/10.1016/S0140-6736(96)03409-5
  4. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-9. https://doi.org/10.1200/JCO.1997.15.5.2040
  5. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-21. https://doi.org/10.1001/jama.299.16.1914
  6. James R, Wan S, Glynne-Jones D, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]. J Clin Oncol 2009;27(18S):LBA4009.
  7. Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012;30:1941-8. https://doi.org/10.1200/JCO.2011.35.4837
  8. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012;30:4344-51. https://doi.org/10.1200/JCO.2012.43.8085
  9. Jeong JU, Yoon MS, Song JY, et al. The results of curative concurrent chemoradiotherapy for anal carcinoma. J Korean Soc Ther Radiol Oncol 2010;28:205-10. https://doi.org/10.3857/jkstro.2010.28.4.205
  10. Lee WS, Chun HK, Lee WY, et al. Anal canal carcinoma: experience from a single Korean institution. Yonsei Med J 2007;48:827-32. https://doi.org/10.3349/ymj.2007.48.5.827
  11. Cho BC, Ahn JB, Seong J, et al. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer 2008;8:8. https://doi.org/10.1186/1471-2407-8-8
  12. National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria v3.0 [Internet]. Bethesda, MD: National Cancer Institute; c2010 [cited 2012 April 4]. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30.
  13. Pavy JJ, Denekamp J, Letschert J, et al. Late effects toxicity scoring: the SOMA scale. Radiother Oncol 1995;35:11-5. https://doi.org/10.1016/0167-8140(95)97448-M
  14. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-39. https://doi.org/10.1200/JCO.1996.14.9.2527
  15. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102:1123-8. https://doi.org/10.1038/sj.bjc.6605605
  16. Konski A, Garcia M Jr, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114-8. https://doi.org/10.1016/j.ijrobp.2007.12.027
  17. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009;52:624-31. https://doi.org/10.1007/DCR.0b013e31819eb7f0
  18. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010;116:4007-13. https://doi.org/10.1002/cncr.25188
  19. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 2013;119:748-55. https://doi.org/10.1002/cncr.27825
  20. Graf R, Wust P, Hildebrandt B, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 2003;65:14-22. https://doi.org/10.1159/000071200
  21. Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001;50:675-80. https://doi.org/10.1016/S0360-3016(01)01510-3
  22. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010;28:5061-6. https://doi.org/10.1200/JCO.2010.29.1351
  23. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2012 Nov 12 [Epub]. http://dx.doi.org/doi:10.1016/j.ijrobp.2012.09.023.
  24. Myerson RJ, Outlaw ED, Chang A, et al. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys 2009;75:428-35. https://doi.org/10.1016/j.ijrobp.2008.11.047

피인용 문헌

  1. Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis vol.9, pp.None, 2013, https://doi.org/10.1186/1748-717x-9-113
  2. Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity vol.21, pp.37, 2013, https://doi.org/10.3748/wjg.v21.i37.10688